Highest-materiality recent filing
Net income $3.8M ($0.05 diluted EPS) vs net loss $11.7M in Q1 2025; revenue $56.4M incl. $50M ICOTYDE milestone from J&J.
Protagonist Q4 net loss $44.4M ($0.69/share); rusfertide opt-out expected Q2 2026
Q4 2025 net loss $44.4M ($0.69 per share) vs Q4 2024 net income $131.7M ($2.11 per share); FY2025 loss $130.1M ($2.05) vs FY2024 income $275.2M ($4.47).
Icotrokinra (oral IL-23R) NDA for psoriasis filed Jul '25; Phase 3 ICONIC-UC and ICONIC-CD initiated Q4 '25; superiority vs deucravacitinib achieved.
Protagonist Q3 net loss $39.3M (-$0.62); cash $678.8M; icotrokinra filed, rusfertide NDA expected Q4
Net loss of $39.3M ($0.62 diluted EPS loss) vs $33.2M loss in Q3 2024.
Protagonist Q2 net loss $34.8M; icotrokinra NDA filed, rusfertide NDA on track
Net loss $34.8M ($0.55/share) vs $30.6M in Q2 2024; license revenue $5.5M from Takeda.
Protagonist Q1 EPS -$0.19; rusfertide Phase 3 positive, ASCO plenary June 1
Cash $697.9M (up from $559.2M Dec 2024); net loss $11.7M (-$0.19/sh) vs income $207.3M in Q1 2024.
Icotrokinra shows positive Phase 2b UC (corrected p-value) and Phase 3 PsO top-line data
Phase 2b ANTHEM-UC: highest dose achieved 63.5% clinical response and 30.2% clinical remission at Wk12 vs 27.0% and 11.1% placebo; p-values corrected to <0.001 and <0.01.
Icotrokinra Phase 3 PsO hits 46% complete skin clearance; UC Phase 2b meets endpoint
Phase 3 ICONIC-LEAD: 46% of icotrokinra patients achieved IGA 0 (completely clear skin) at Week 24; 74% IGA 0/1.
77% of rusfertide patients achieved clinical response vs 33% placebo (p<0.0001) during weeks 20-32.
Protagonist reports Q4 net income $131.7M; cash $559.2M; upcoming Phase 3 readouts in March 2025
Net income of $131.7M in Q4 2024 ($2.11 basic EPS) vs $27.3M in Q4 2023; FY 2024 net income $275.2M vs net loss of $79.0M in FY 2023.
Protagonist announces positive Phase 3 results for icotrokinra; earns $165M milestone
ICONIC-LEAD met co-primary endpoints: 64.7% achieved IGA 0/1, 49.6% PASI 90 at week 16 vs placebo 8.3% and 4.4%.
Protagonist Q3 net loss of $33.2M, cash $583M; key readouts expected in Q4 2024 and Q1 2025
Net loss of $33.2M ($0.54 per share) vs $34.1M loss in prior-year Q3.
Protagonist Q2 net loss $30.6M; cash $595.4M; JNJ-2113 Phase 3 data expected Q4 2024
Q2 net loss of $30.6M ($0.50/share) vs $38.5M loss in Q2 2023; six-month net income $176.7M from Takeda upfront.
Protagonist Therapeutics shareholders approve doubling of authorized common shares to 180M
Shareholders approved amendment to increase authorized common shares from 90M to 180M, effective June 21, 2024.
Protagonist Q1 net income $207.3M on $255M Takeda revenue; cash runway through Q4 2027
Net income of $207.3M ($3.26 diluted EPS) vs net loss of $33.7M in Q1 2023; revenue $255M from Takeda rusfertide license.
Protagonist reports Q4 profit, $300M Takeda deal extends cash runway through 2027
Entered worldwide Takeda collaboration for rusfertide; $300M upfront, US profit share, opt-out up to $400M.
Protagonist Therapeutics signs $300M upfront collaboration with Takeda for rusfertide
Takeda pays $300M upfront within 30 days of HSR clearance; 50/50 profit-loss share in U.S.
Effective January 1, 2025, Suneel Gupta, Ph.D., Protagonist Therapeutics, Inc.’s Chief Development Officer, transitioned to Executive Vice President, Clinical Development.
On September 17, 2024, Daniel N. Swisher Jr., a member of the Board of Directors (the “Board”) of Protagonist Therapeutics, Inc. (the “Company”) and a member of the Audit Committee of the Board, resigned from the Board, effective September 17, 2024.
Max materiality 1.00 · Median 0.80 · Most common event earnings